<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878122</url>
  </required_header>
  <id_info>
    <org_study_id>35RC15_3007_FaCliBioCCo</org_study_id>
    <nct_id>NCT02878122</nct_id>
  </id_info>
  <brief_title>Study of Predictive Factors of Chemoresistance in Ovarian Cancer</brief_title>
  <acronym>FaCliBioCCo</acronym>
  <official_title>Study of Predictive Factors of Chemoresistance in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking
      surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but
      most often a recurrence occurred in the first 18 months. Early recurrence signs
      chemoresistance and palliative treatment. The study of predictive clinical or biological
      factors is required to adapt therapeutic and develop new treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chemoresistance defined by clinical recurrence</measure>
    <time_frame>6 months after the end of chemotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemoresistance defined by biological recurrence</measure>
    <time_frame>6 months after the end of chemotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemoresistance defined by radiological recurrence</measure>
    <time_frame>6 months after the end of chemotherapy</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with epithelial ovarian cancer</arm_group_label>
    <description>Cancer treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cancer treatment</intervention_name>
    <description>Chemotherapy and laparoscopic surgery</description>
    <arm_group_label>Patients with epithelial ovarian cancer</arm_group_label>
    <other_name>Carboplatin, Taxol</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      surgical sampling, blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with epithelial ovarian cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient &gt; 18 years of age

          -  patient with histological proven epithelial ovarian cancer

        Exclusion Criteria:

          -  patients who can not give their own consent

          -  patients without ovarian cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAVOUE Vincent, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAVOUE Vincent, Pr</last_name>
    <email>vincent.lavoue@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>LAVOUE</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAVOUE Vincent, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>chemo resistance</keyword>
  <keyword>predictive factors</keyword>
  <keyword>cohort study</keyword>
  <keyword>bio bank</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

